To better stratify the AML patients into different risk groups, a scoring system incorporating 10 prognostic markers, including age, WBC counts, cytogenetics at diagnosis, NPM1/FLT3-ITD and mutations of CEBPA, IDH2, TP53, DNMT3A, RUNX1 and WT1, into survival analysis was formulated based on the results of our Cox proportional hazards model. Here, FLT3 is linked to acute myeloid leukemia.